How to Structure a Board Paper Seeking Approval for a New Market Entry

A board paper proposing new market entry is not a sales document. It is a decision instrument. If directors cannot see the downside case as clearly as the upside, cannot trace the assumptions to evidence, and cannot understand what they are being asked to approve versus what remains open, the paper has failed, regardless of how compelling the opportunity.

Key Executive Takeaways

• A strong market entry paper leads with the decision being requested, the conditions attached, and the exit triggers, not the opportunity narrative.
• The quality of your assumption base and your treatment of downside scenarios will determine board confidence more than the strategic rationale itself.
• Regulatory, conduct, and operational readiness must be presented as genuine capability, not as boxes ticked, because the board will be accountable for what follows approval.

Lead with the decision, not the story

Most market entry papers open with context: market size, competitor moves, strategic fit. By the time the board reaches the ask, they have absorbed a persuasive narrative and lost the critical distance needed to interrogate it.

Invert this. The first page should state: what you are asking the board to approve, the capital or resource commitment, the key conditions, the decision points reserved for later, and the circumstances under which the entry would be paused or reversed. Everything that follows exists to support or test that ask.

Structure the paper around what the board must judge

A board approving market entry is making four distinct judgements. Structure the paper so each is addressed on its own terms.

Strategic rationale. Why this market, why now, and why us. Be specific about the capability or position that gives you the right to compete. If the answer is that the market is growing and adjacent to current activities, that is weak. Boards have seen that paper before and watched it fail.

Commercial case. Revenue build, cost base, capital requirements, payback, and sensitivity. The sensitivity analysis is where credibility is won or lost. Show what happens if customer acquisition costs run 50% above plan, if pricing compresses, if the ramp takes twice as long. If every scenario still clears the hurdle rate, the board will suspect the modelling, rightly.

Risk and regulatory readiness. This is not a compliance appendix. For regulated firms, entering a new market, whether a new jurisdiction, product line, or customer segment, triggers obligations around permissions, conduct frameworks, financial crime controls, operational resilience, and often SMR allocations. Set out what is required, what is in place, what is being built, and the timeline. Where you are relying on existing frameworks, explain why they transfer. Where you are not, show the plan and the owner.

Execution capability. Who is accountable, what the operating model looks like, where the gaps are, and how they will be closed. Boards approve entries that fail not because the strategy was wrong but because no one on the executive had capacity to run it properly.

Treat assumptions as evidence, not decoration

List the material assumptions explicitly. For each, state the source, the confidence level, and what would cause it to break. The assumptions that matter most are usually about customer behaviour, competitor response, and the time required to reach operational maturity. Internal estimates dressed as market data are the single most common failure.

Where assumptions are weakly evidenced, say so. A board that discovers hidden fragility after approval will not trust the next paper from the same author.

Pre-empt the hard questions

Before submission, write down the five questions you least want asked. Address them in the paper. If you cannot answer them, the paper is not ready. Common ones: what is our genuine differentiation against incumbents, what is the cost of exit if this does not work, how does this affect our capital position under stress, what conduct risks arise with customers we have not served before, and what is the opportunity cost of the management attention required.

Define what approval actually means

Avoid open-ended approvals. Specify the stage gates: initial investment, pilot phase, full launch. Define the metrics and the review points. Set the conditions under which further board approval is required. This protects both the executive and the board, and it forces discipline on the team running the entry.

What good looks like

A good paper is shorter than most. It is specific where others are vague, cautious where others are confident, and clear about what remains unknown. It gives the board a decision they can defend to a regulator, to shareholders, and to themselves in two years.

Before you submit, ask one question: if this entry fails, will the board feel they were given what they needed to decide well. If not, rewrite.

Frequently Asked Questions

How long should a market entry board paper be?

Twenty to thirty pages for the main paper, with appendices for detailed financials, regulatory analysis, and competitor assessment. If the core argument cannot be made in that space, the thinking is not yet clear enough.

Should the paper include a recommendation or present options?

Include a clear executive recommendation, but present the realistic alternatives you considered, including not entering, entering at smaller scale, or partnering. Boards distrust papers that present only one path.

How should regulatory engagement be reflected?

If the entry requires new permissions or variation of existing ones, set out the engagement plan with the regulator, the expected timeline, and the risks to that timeline. Do not present regulatory approval as a formality. Treat it as a substantive workstream with its own owner.

What is the right level of financial detail?

Enough for the board to understand the shape of the investment, the drivers of return, and the sensitivities. Full model outputs belong in an appendix. The board needs to see the logic, not the spreadsheet.

Who should sponsor the paper?

The executive who will be accountable for delivery, not the strategy function or the business development team. If the person presenting is not the person who will run it, the board will notice, and should.